India is increasing supervision over fast-growing weight-loss and diabetes medications, particularly GLP-1 receptor agonists, due to surging demand and the expected introduction of more affordable generic versions. The Indian Pharmacopoeia Commission (IPC) under the Ministry of Health has been assigned the task of systematically gathering and analyzing adverse event reports associated with these drugs to enhance post-marketing surveillance and promptly address any safety issues. This move is part of a broader regulatory effort to keep up with the rapid adoption of these treatments, especially with improving affordability.
With the patent expiration of semaglutide, a crucial component in popular weight-loss therapies, the market anticipates the arrival of cheaper generic alternatives, potentially broadening access while also increasing the risk of misuse. The recent tightening of surveillance complements previous enforcement measures by the Drug Controller General of India (DCGI), who has intensified inspections to crack down on unauthorized sales and promotions of GLP-1 drugs. Authorities have conducted audits on 49 entities nationwide, including online pharmacy warehouses, wholesalers, retailers, and weight-loss clinics, focusing on identifying violations like selling without prescriptions, improper prescribing practices, and misleading marketing.
Notices have been issued to violators, with the government cautioning that non-compliance could result in license cancellations, financial penalties, and legal action. The government has emphasized that only qualified specialists, such as endocrinologists, internal medicine experts, and cardiologists, are permitted to prescribe these medications. Earlier in March, manufacturers were instructed to stop misleading advertisements and promotions that could encourage unsupervised usage.
GLP-1 receptor agonists, commonly used for type 2 diabetes treatment and increasingly for weight loss, function by stimulating insulin release and reducing appetite through delayed gastric emptying. Despite their benefits, health authorities have highlighted potential side effects ranging from nausea and vomiting to more severe risks like pancreatitis, kidney injury, and bowel obstruction.
